Translational Use of Intradermal Needle-free Injector to facilitate and optimize global fractional dose HPV vaccine administration

项目摘要 子宫颈癌是女性第四大常见癌症，约有57万新病例 2018年死亡人数超过30万，其中大部分发生在低收入和中等收入国家（布雷， 2018年）。在印度尼西亚，宫颈癌是妇女中第二大流行癌症， 32，000例新病例和18，000例死亡（全球癌症观察站，2019年）。研究表明，人类 乳头状瘤病毒（HPV）感染是宫颈癌的主要病原体（Bosch，2002）。在2017年， 世卫组织发布了一份HPV疫苗立场文件，指出HPV疫苗应纳入国家疫苗接种计划。 免疫方案的主要目标人群是9-14岁的女孩， 活跃（世界卫生组织，2017年）。接种疫苗是最具成本效益和效率的 人乳头瘤病毒引起的宫颈癌的预防方法。目前，HPV疫苗已 在全球近100个国家（52%）推出，主要是中高收入和高收入国家 国家然而，在负担最重的国家（低收入和中等收入），获得这种服务的机会仍然滞后。 此外，全球卫生组织此前收集的数据显示， HPV疫苗的依从率，部分归因于针头恐惧症。据预测，这一问题将 除非采取新的疫苗接种策略。 在这份直接进入第二阶段的提案中，我们将探索减少剂量的可行性和潜在益处 HPV疫苗的皮内接种策略。在这项更大的研究中，我们将评估 给药以确定免疫原性、反应原性以及患者和护理人员的水平 接受每一个。在资源最少的情况下，无针注射分娩的好处 预计将包括剂量节省，增加依从性和预防针刺损伤 和疾病传播。这些研究的结果将提供临床数据来回答主要的问题。 目前HPV疫苗计划的问题：1）疫苗剂量的可用性; 2）成本; 3） 可接受性和合规性。这些数据将是促进未来政策讨论和全球 关于在印度尼西亚和其他发展中国家接种fiHPV疫苗的卫生战略 国家紧接着的下一步将包括计划在多个领域开展更大规模的推广活动 在印度尼西亚，特别是在疫苗接种依从性历来较低的偏远地区。 最终，这些研究将被用作提高对PharmaJet Tropis针的认识的工具- 免费注射系统作为一种用于fiHPV施用的方法，可以在全国范围内和世界范围内帮助 疫苗的依从性和对世卫组织和卫生部建议的时间表的可接受性 健康

PROJECT SUMMARY Cervical cancer is the fourth most common cancer in women, contributing to about 570,000 new cases and more than 300,000 deaths in 2018, most of it occurs in the low- and middle-income countries (Bray, 2018). In Indonesia, cervical cancer is the second most prevalent type of cancer among women, with 32,000 new cases and 18,000 deaths (Global Cancer Observatory, 2019). It has been shown that human papillomavirus (HPV) infection is the major causative agent of cervical cancer (Bosch, 2002). In 2017, WHO released an HPV vaccine position paper that stated HPV vaccines should be included in national immunization programs with its primary target population is 9-14 year old girls, prior to becoming sexually active (World Health Organization, 2017). Vaccination represents the most cost-effective and efficient way for the prevention of cervical cancer caused by human papillomavirus. Currently, HPV vaccine has been introduced in nearly 100 countries globally (52%), mainly in the upper-middle- and high-income countries. However, its access in the highest burden countries (low and middle income) remains lagging. Furthermore, previous data collected by global health organizations have shown continued low compliance rates for HPV vaccines, partly attributable to needle-phobia. It is predicted that this issue will persist unless a new strategy for vaccination is introduced. In this direct to Phase II proposal, we will explore the feasibility and potential benefits of a reduced dose intradermal strategy for HPV vaccines. In this larger study, we will evaluate doses and routes of administration to determine the immunogenicity, reactogenicity, and levels of patient and caregiver acceptance for each. In settings with minimal resources, the benefits of delivery with needle-free injection are predicted to include dose savings, increased compliance, and the prevention of needle-stick injuries and disease transmission. The results from these studies will provide clinical data to answer the main problems with the current HPV vaccine schedule: 1) availability of vaccine doses; 2) cost; and 3) acceptability & compliance. This data will be a first step to facilitate future policy discussions and global health strategies regarding administration of fiHPV vaccines across Indonesia and other developing countries. The immediate next steps will include planning a larger roll-out campaign across multiple areas of Indonesia, notably in further remote areas where vaccination compliance has been historically low. Ultimately, these studies will be used as a tool to increase awareness of the PharmaJet Tropis Needle- free injection system as a method for fiHPV administration that may aid in country-wide and worldwide vaccine compliance and acceptability to schedules as recommended by the WHO and Ministries of Health.